TARGET TO SPECIFIC LYMPHOID CELLS. PHASE I. MACROPHAGE TARGETING.

Award Information
Agency:
National Science Foundation
Branch
n/a
Amount:
$35,000.00
Award Year:
1983
Program:
SBIR
Phase:
Phase I
Contract:
n/a
Award Id:
763
Agency Tracking Number:
763
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
939 East Walnut St., Pasadena, CA, 91106
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
JOSEPH A. ULIANA PH.D.
PRINCIPAL INVESTIGATOR
() -
Business Contact:
() -
Research Institution:
n/a
Abstract
A THREE PHASE PROJECT IS PROPOSED TO COMMERCIALIZE FORMULATIONS OF PHOSPHOLIPID VESICLES CAPABLE OF DELIVERING IMMUNOGENIC SUBSTANCES TO SPECIFIC LYMPHOID CELLS. PHASE I IS A PROOF OF CONCEPT STUDY DESIGNED TO DEMONSTRATE THAT A VESICLE FORMULATION KNOWN TO AGGRESSIVELY TARGET TO MACROPHAGE IN VITRO CAN EVOKE STRONG MACROPHAGE MEDIATED IMMUNE RESPONSES TO OTHERWISE WEAK OR NONIMMUNOGENIC HAPTEN CONJUGATES IN VIVO. PHASE I EXPERIMENTS SPECIFICALLY ADDRESS THE MACROPHAGE MEDIATED B-CELL RESPONSE AND ARE DESIGNED TO DETERMINE THE SIGNIFICANCE OF THE SIZE OF THE HAPTEN CARRIER WHEN TARGETED WITH VESICLES. PHASE I SHOULD SUGGEST ANSWERS TO THE FOLLOWING QUESTIONS: 1) IS AN ENDOCYTOSED VESICLE PROCESSED AS AN IMMUNOGEN BEFORE OR AFTER LYSIS BY MACROPHAGE? 2) ARE LYSOZOME LABILE CARRIERS PROCESSED AS ANTIGENS OR DEGRADED WHEN ENDOCYTOSED WITHIN TARGETED VESICLES? 3) ARE HAPTEN-CONJUGATES, TARGETED TO MACROPHAGE BY VESICLE ENCAPSULATION, IMMUNOGENIC AT LOWER DOSAGES THAN CONVENTIONALLY INTRODUCED HAPTEN-CONJUGATES? SUCCESSFUL COMPLETION OF PHASE I WILL DEMONSTRATE THAT IMMUNE RESPONSE CAN BE ALTERED BY PRESENTING CHEMICAL SUBSTANCES TO SPECIFIC CELLS IN A MICROENCAPSULATED FORMULATION. PHASE II WILL EXTEND THIS PRELIMINARY INVES- TIGATION OF DELIVERING HAPTEN-CONJUGATE FORMULATIONS TO MACROPHAGE TO INCORPORATE HELPER T-CELL PARTICIPATION IN THEINITIAL ANTICIPATED T-CELL INDEPENDENT RESPONSE. THE PRODUCTION OF IMMUNE RESPONSES TO WEAKLY IMMUNOGENIC OR NON-IMMUNOGENIC MATERIALS HAS SIGNIFICANT SCIENTIFIC AND MEDICALAPPLICATIONS.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government